Introduction: Pemphigus vulgaris (PV) is a chronic, autoimmune, vesiculobullous disease.
publications from the 1970s reported high-dose, prolonged corticosteroid use and significant associated side effects. Later reports described use of corticosteroids along with steroid-sparing adjuvants, which allows a reduction in the total dose of corticosteroids and a reduction in observed mortality and morbidity. For the majority of patients in these reports, a long-term course on medications lasting about 5-10 years was observed; however, subgroups of patients requiring shorter courses or needing longer-term therapy have also been described.
INTRODUCTION
Pemphigus vulgaris (PV) is a chronic, autoimmune, mucocutaneous, vesiculobullous disease [1] .
The word pemphigus comes from the Greek word pemphix, which means blister [2] . It is a rare disease with estimated worldwide annual incidence of 0.1-0.5 per 100,000 [3] . It occurs in all racial and ethnic groups with the highest incidence seen in Ashkenazi Jews [4] .
Occurrence is most common during the fifth and sixth decades of life, although a few cases have been reported in children [5] .
In the majority of cases, PV initially presents with lesions on the oral mucosa [3] . Often the first sites affected are those exposed to frictional trauma including the buccal and lateral tongue mucosa along the occlusal level, or the gingiva, but PV can occur on any oral site particularly if exposed to sharp or acidic foods. The lesions start as vesicles which rupture easily leaving erosions and ulcers.
The pathogenesis of pemphigus involves the presence of circulating and tissue-bound autoantibodies to the keratinocyte cell surface desmosomal molecules desmoglein 3 (Dsg3) and desmoglein 1 (Dsg1). Dsg3 and Dsg1 belong to the cadherin superfamily involved in cell-cell adhesion. These autoantibodies cause loss of cell-cell adhesion between epithelial cells, which results in suprabasilar intraepithelial vesicle formation [4, 6] .
Diagnostic tests include perilesional mucosal or skin biopsy for histologic examination and direct immunofluoresence testing. Histologic findings include presence of intraepithelial blisters and suprabasilar acantholysis; direct immunofluorescence findings include IgG deposits and less commonly IgM and C3 deposits in intercellular spaces in the epithelium. Blood tests include ELISA testing for Dsg3 and Dsg1 autoantibodies [7] .
Prior to availability of corticosteroid therapy in the 1950s, PV had a very high fatality rate.
While many treatment options are now available, corticosteroids in combination with other drugs still form the mainstay of treatment. Mortality from pemphigus has decreased significantly in the last half century and is now usually due to adverse effects of the medications used [8, 9] .
As a result of the relative rarity of pemphigus, there are very few randomized controlled trials. However, numerous observational studies, case reports, and case series have been published that report on the treatment of pemphigus. The objective of this review was to summarize the findings from all of the reported human studies including observational studies and case reports.
METHODS
Publications relating to treatment of PV were identified by searches of electronic databases including PubMed, Cochrane, and Google Scholar through May 2015. Keywords used included pemphigus vulgaris, autoimmune vesiculobullous disease, corticosteroids, azathioprine, rituximab, mycophenolate mofetil, methotrexate, and IVIg. The full-text versions of the papers identified were obtained.
The bibliography of these papers was also reviewed to identify any additional papers that did not appear in the electronic search. Only English-language papers describing treatment outcomes of patients with PV were included in this review. A total of 89 papers, which included 21 case reports, 47 case series, 8 RCTs, and 13 observational studies, were included. These papers were reviewed to obtain information on publication date, type of study done, age of the patients, extent of lesion involvement (skin and mucosa), previous treatments if any, medications used, duration of use of previous medications before new ones were started, duration to first improvement after the start of medications, follow-up duration, concomitant medication used along with main drug, outcome, duration on medication, adverse effects of drugs, and antibody titer changes after treatment. This information is summarized in Tables 1, 2 , 3, 4, 5 and 6.
Definitions for some of the terms relating to treatment outcomes listed in the tables are described in a consensus statement published in 2008 [10] as follows:
Complete remission off therapy: Absence of new and/or established lesions while the patient is off all systemic therapy for at least 2 months.
Complete remission on therapy: Absence of new or established lesions while the patient is receiving minimal therapy.
Minimal therapy: Less than, or equal to, 10 mg/day of prednisone (or the equivalent) and/or minimal adjuvant therapy for at least 2 months.
Minimal adjuvant therapy:
Half of the dose required to be defined as treatment failure. Partial remission on minimal therapy: Presence of transient new lesions that heal within 1 week while the patient is receiving minimal therapy, including topical steroids [10] .
However not all papers included in this review have described their specific definition for these terms. If these terms were mentioned in the publication, we have listed them in the tables as mentioned in the publication. This article is based on previously conducted studies and does not involve any studies of human or animal subjects performed by any of the authors.
RESULTS

Corticosteroids (CS)
Since the time of their approval in the 1950s, corticosteroids have been the mainstay of treatment of PV.
Mechanism of Action
Corticosteroids have strong anti-inflammatory and immunosuppressive effects. They affect almost every aspect of the immune system. They are potent inhibitors of NFkappa B activation and have effects on leukocyte movement, leukocyte function, and humoral factors. In addition they have inhibitory effects on many known cytokines [11] . The first case series on corticosteroid use in PV was published in 1972.
The publications reporting use of corticosteroids in PV are summarized in Table 1 . This table includes papers that had systemic corticosteroids as the primary Table 1 Corticosteroids Author/year cohort study (n = 74), two randomized controlled trials (n = 20 and n = 120), and five retrospective cohort studies (n = 15, n = 16, n = 23, n = 32, and n = 154) are summarized in the Table 1 . In all, the total number of cases in these 31 publications was 2164 out of which 2141 were PV patients, and the rest had pemphigus foliaceous or pemphigus vegetans or pemphigus erythematous. These 31 reports originated from the USA, Israel, Iran, Sri Lanka, India, Scotland, Italy, Greece, Spain, the Netherlands, Germany, France, Singapore and Turkey.
Age at initial diagnosis of PV in these publications ranged from 4 to 89 years.
Medication Use
Prednisone and prednisolone were the most commonly used corticosteroids. Starting doses Duration on medication included the time period on medication prior to the start of follow-up to this paper ranged from 15 to 180 mg prednisone equivalent daily in all but one of the reports where doses as high as 400 mg daily were used [12, 13] .
Duration of PV Before Corticosteroids Were Started
This ranged from 0.15 months to 6 years.
Duration of Total Follow-up
Duration of total clinical follow-up of the individual patients ranged from 9 months to 22 years.
Duration Before Any Clinical Improvement Was Noted
Seven publications reported on the duration before any clinical improvement after the start of corticosteroids was apparent, and this ranged from 3 days to 19 weeks [14] [15] [16] [17] [18] [19] [20] . Duration to complete remission off therapy was reported in 15 articles, and ranged from 4 to 120 months (10 years) in 321 patients.
Duration to Start of Taper of Corticosteroids
Remission
Of a total of 2141 patients reported on in Table 1 , at the end of follow-up 97 patients had achieved partial remission on therapy, 797 patients had achieved complete remission on therapy, and 321 patients had achieved complete remission off therapy. A total of 485 patients were still being treated at the time of publication, 156 patients were lost to follow-up, death occurred in 177 patients, and 47 patients were classified as non-responders and referred elsewhere for treatment.
Duration of Medication Use
Total duration of medication use for all reported patients including those still on therapy at the time of publication ranged from 1.5 to 240 months (20 years).
Follow-up Duration After Discontinuation of Medications
Follow-up ranged from 2 to 156 months (13 years)
after discontinuation of treatment in the 321 patients with complete remission off therapy, during which time there was no recurrence.
Mortality
Death occurred in a total of 177 of 2141 patients 
Adverse Effects
Adverse effects from corticosteroids reported in these papers included Cushingoid symptoms, 
Mechanism of Action
This drug restricts synthesis of DNA, RNA, and proteins by inhibiting metabolism of purine. It also interferes with cellular metabolism and mitosis [8] .
Publication Type, Patient Profiles, and Sample
Sizes
The studies reporting use of AZA in PV are summarized in Tables 1 and 2 . Of the 31 papers in Table 1 , 17 had included azathioprine as one of the treatment modalities. Table 2 includes only those publications that reported on comparative analyses of outcomes for patients on prednisone alone vs. those on prednisone in combination with azathioprine. The first case series on use of AZA in PV was published in
1986.
One randomized double blind controlled study (n = 56) and two retrospective cohort studies (n = 48 and n = 36) are summarized in Table 2 . In all, a total of 140 patients were included in these three reports.
Age at initial diagnosis of PV in these publications ranged from 16 to 83 years.
Medication Use
The dosage of azathioprine used was 40 mg/day up to 3 mg/kg/day in all reports. Prednisone was used concomitantly with azathioprine in all reports. Azathioprine was added at the onset of treatment in the three reports in Table 2 and sometime after onset of corticosteroid use in the reports in Table 1 .
Duration of PV Before Azathioprine Was
Started in the Reports Summarized in Table 2 This ranged from 4 to 10 months.
Duration of Follow-up in the Reports
Summarized in Table 2 Duration of clinical follow-up of the individual patients on azathioprine in these reports ranged from 12 months to 10 years.
Duration to Complete Remission (On and Off therapy) for the Azathioprine Plus Prednisone
Group in Table 2 Duration to complete remission on therapy was reported in three articles and, ranged from 6 to 12 months, in 67 patients. Duration to complete remission off therapy was reported in two articles and, ranged from 6 to 12 months, in eight patients.
Patients on prednisone and azathioprine had better responses as compared to patients on prednisone alone, with more patients achieving remission, and with fewer side effects.
Remission
Of a total of 140 patients, at the end of follow-up 11 patients had achieved partial remission and mean duration to achieve that was 234.4 days, 67 patients had achieved complete remission on therapy, and eight patients had achieved complete remission off therapy. Six patients were still being treated at the time of publication. No response was seen in 17 patients. Treatment failed in five patients.
Death occurred in 13 patients and 13 patients were lost to follow-up. Mycophenolate used in patients with refractory pemphigus vulgaris (previous treatment with corticosteroids and azathioprine was unsuccessful in achieving remission) are reported in Table 3 Pred Duration on medication included the time period on medication prior to the start of follow-up to this paper Table 4 Intravenous immunoglobulin
Author/year Table 5 Methotrexate
Author/year Whether PR or CR-NM Table 6 continued Author/year Table 6 continued Table 6 continued Author/year Table 6 continued Headache, asthenia, fever, chills, nausea, pyelonephritis Table 6 continued Table 6 continued Duration on medication included the time period on medication prior to the start of follow-up to this paper Adverse Effects Reported in Table 2 Adverse effects in patients on azathioprine and corticosteroids reported in these publications included leukopenia, anemia, thrombocytopenia, pancytopenia, hepatotoxicity, hypertension, gastrointestinal problems, lethargy, weight gain, muscle weakness, adrenal suppression, alopecia, and rash-like skin disorders.
Mycophenolate Mofetil (MMF)
Mycophenolate Mofetil was approved by the FDA in 1995 as an immunosuppressant to prevent organ transplant rejection.
Mechanism of Action
After oral administration, mycophenolate is absorbed rapidly and then gets converted to the active metabolite mycophenolic acid (MPA).
This active metabolite inhibits inosine monophosphate dehydrogenase selectively and hence inhibits de novo pathway of purine synthesis in T and B cells, which results in inhibition of T and B cell proliferation [20] .
Publications reporting use of MMF as an adjuvant to corticosteroids in PV were included in Table 1 . Additional papers which have reported on the use of mycophenolate in patients with refractory PV (previous treatment with corticosteroids and azathioprine was unsuccessful in achieving remission) are summarized in Table 3 .
Of 31 papers in Table 1 , three had included MMF as one of the treatment modalities. The total number of patients treated with MMF in these 10 reports was 247.
Age at initial diagnosis of PV in these publications ranged from 6 to 78 years.
Medication Use and Duration of PV Before MMF Was Started
Medication use and duration of PV before MMF was started ranged from 1 month to 14 years.
During this period patients were on a combination of corticosteroids and azathioprine. At the time mycophenolate was added, the azathioprine was discontinued; however, the patients continued to be on corticosteroids. One publication (Powell et al.) reported on patients in whom multiple medications like methotrexate, cyclophosphamide, IVIg, dapsone, gold, thalidomide, and minocycline along with azathioprine and corticosteroids were tried prior to addition of mycophenolate [21] .
The starting dosage of mycophenolate mofetil used was 2-3 g/day in all reports.
Duration of Follow-up
Duration of clinical follow-up of the individual patients after the start of MMF therapy ranged from 5 to 130 months.
Duration Before Any Clinical Improvement
Was Noted First improvement in lesions was noted after 2-24 weeks after addition of mycophenolate to the existing medication regimen.
Duration to Complete Remission (On and Off
Therapy) After Addition of MMF Duration to complete remission on therapy was reported in six articles and, ranged from 2 to 16 months, in 104 patients.
Duration to complete remission off therapy was reported in one article and, ranged from 24 to 36 months, in 17 patients.
Remission
Of a total of 247 patients, 104 patients achieved complete remission on therapy and 17 patients achieved complete remission off therapy. A total of 76 patients achieved partial remission, and the duration to achieve that ranged from 129 to 150 days after the start of therapy. Failure of MMF was mentioned in four reports (N = 176) in 18 patients who were referred for treatment with rituximab or IVIg. Two patients were still being treated at the time of publication, 29 patients were lost to follow-up or withdrawn from study, and death occurred in one patient.
Adverse Effects
Adverse effects in patients on mycophenolate and corticosteroids reported in these publications included gastrointestinal problems, myalgia, neutropenia, and lymphopenia, which were the most common side effects reported. Headache, increased fasting blood glucose level, and hypertension, nausea, depression, pyrexia, redistribution of body fat, eye disease, weight gain, fatigue, and arthralgia were also reported.
In the one publication where enteric coated mycophenolate sodium was used, the side effects reported were headache and increased fasting blood glucose level.
Intravenous Immunoglobulin (IVIg)
IVIg was approved by the FDA for primary immune deficiency in 1952 [22] .
Mechanism of Action
Intravenous immunoglobulins (IVIg) are obtained from a plasma pool of thousands of donors [22] . These immunoglobulins neutralize and slow down the production of circulating pemphigus antibodies [23] .
Publication Type, Patient Profiles, and Sample Sizes
The studies reporting use of IVIg in PV are summarized in Table 4 . The first case series on IVIg in PV was published in 2002.
One case series (n = 6), two case reports describing single patients, and one randomized placebo-controlled double-blind trial (n = 40) are summarized in Age at initial diagnosis of PV in these publications ranged from 41 to 78 years.
Medication Use
The dosage of IVIg used was 400 mg/kg/day for 5 days followed by long-or short-term single doses of 400 mg/kg/day every 6 weeks for 6 months to 1 year. Concomitant drugs mainly used were corticosteroids in the published studies.
Duration of PV Before IVIg Was Started
This ranged from 2 months to 5 years. 
Duration to Start of Taper of Corticosteroids
Only one case series of six patients described the duration to the start of taper of corticosteroids and only mentioned that the median time was 16 days after the start of IVIg infusions.
Duration to Complete Remission (On and Off
Therapy)
This information was not available from the publications. However, all reports discussed improvement in all patients treated with IVIg; in six patients this was achieved within 3 weeks and in 29 patients within 3-12 months. Thirteen patients in the placebo group had no improvement. Table 4 Headache, abdominal discomfort, nausea, constipation, lymphopenia, hepatitis C, and palpitations.
Adverse Effects in Patients on IVIg Reported in
Methotrexate
Methotrexate was approved by the FDA for psoriasis in 1971 and for rheumatoid arthritis in 1988.
Mechanism of Action
Methotrexate inhibits the metabolism of folic acid and is used as a chemotherapeutic and immunosuppressive agent. Methotrexate allosterically inhibits dihydrofolate reductase, which plays a role in tetrahydrofolate synthesis.
As folic acid is essential for normal cell growth and replication, methotrexate is effective against malignant cell growth and has anti-inflammatory effects [24] .
Sizes
The studies reporting use of methotrexate in PV are summarized in Table 5 . The first case series on MTX in PV was published in 1969.
Publications reporting use of methotrexate in PV were included in Table 1 (7 of 31 papers included methotrexate), and additional papers that reported on the use of methotrexate as the initial adjunctive treatment to corticosteroids are summarized in Table 5 .
Six case series were included, with the number of cases included in the individual papers ranging from 3 to 53 cases (total of 121 patients in six case series), and one retrospective cohort study (n = 30) are summarized in the tables. In all, a total of 151 patients treated with MTX are reported in seven studies.
Age at initial diagnosis of PV in these publications ranged from 20 to 83 years.
Medication Use
The dosage of MTX used in these publications ranged from 12.5 to 150 mg/week. Concomitant drug used along with methotrexate was prednisone.
Duration of PV Before Methotrexate Was Started
This ranged from 11 months to 7 years. Duration to complete remission off therapy was reported in one article and, ranged from 3 months to 8 years, in 14 patients.
Duration of Follow-up
Remission
Of a total of 151 patients, at the end of follow-up, 56 patients had achieved partial remission and the duration to achieve that was within 6 months after the start of MTX therapy; 51 patients had achieved complete remission on therapy; and 14 patients had achieved complete remission off therapy.
Twelve patients were lost to follow-up.
Treatment was not effective in nine patients. Death unrelated to MTX occurred in six patients.
Adverse Effects in Patients on MTX Reported in Table 5 Nausea, leukopenia, GI upset, fatigue, bacterial infection, bronchopneumonia, septicemia, necrotizing gingivitis, diarrhea, and pyoderma. 
Mechanism of Action
Rituximab is a human-mouse chimeric monoclonal antibody to CD20 antigen on B cells. CD20 is a membrane protein that is involved in activation and proliferation of B cell [25] .
Publication Type, Patient Profiles, and Sample
Sizes
The studies reporting use of rituximab in PV are summarized in Table 6 . The first case series on PV treated by rituximab was published in 2002.
Publications which have reported on the use of rituximab in patients with refractory PV (previous treatment with corticosteroids, azathioprine, methotrexate, mycophenolate, IVIg, and cyclophosphamide were unsuccessful in achieving remission) are summarized in Table 6 .
Nineteen case series were included, with the number of cases included in the individual papers ranging from 3 to 84 cases (total of 339 patients in 19 case series), 24
were case reports describing single patients, three open label pilot studies (n = 5, n = 9, and n = 17), one randomized prospective trial (n = 15), two retrospective analysis (n = 25
and n = 19), and one phase 2 clinical trial (n = 40) are summarized in the tables. In all, a total of 493 patients were treated with rituximab.
Age of patients treated with rituximab for PV in these publications ranged from 15 to 86.
Medication Use
The dosage of rituximab used was 375 mg/m 2 body surface area (BSA) once weekly for 4 weeks or two infusions of 1000 mg at 2 weeks apart. Previously failed treatments before rituximab were prednisone, MMF, AZA, IVIg, MTX, dapsone, CyclP, plasmapheresis, protein A immunoadsorption, cyclosporine, dexamethasone, and gold. Concomitant drug used was prednisone, MMF, AZA, and IVIg.
Duration of PV Before Rituximab Was Started
This ranged from 1 months to 23 years.
Duration of Follow-up
Duration of clinical follow-up of the individual patients after the start of rituximab therapy ranged from 6 to 80 months.
Duration Before Any Clinical Improvement Was Noted
First improvement in lesions was reported within 2 weeks to 8 months after the first rituximab infusion.
Duration to Complete Remission (On and Off
Therapy)
Duration to complete remission on therapy was reported in 32 articles and, ranged from 1 to 36 months, in 184 patients. Duration to complete remission off therapy was reported in 22 articles and, ranged from 2 to 59 months, in 229 patients.
Remission
Of a total of 493 patients reported in Table 6 , at the end of follow-up, 80 patients had achieved partial remission, and duration to achieve that ranged from 3 to 27 months; 184 patients achieved complete remission on therapy; and 229 patients achieved complete remission off therapy. Death due to sepsis occurred in three patients. Relapses were seen in nine patients. No response to rituximab was seen in 11 patients.
However, these patients had response after addition of IVIg or additional cycles of rituximab.
Adverse Effects in Patients on Rituximab Reported in Table 6 Local pain, nausea, cough, chills, sepsis, and angioedema related to infusion.
OTHER MEDICATIONS
Other Less Commonly Used Adjuvants from Studies Listed in Table 1 Gold salts These are widely used in treatment of rheumatoid arthritis. Their action is related to their T cell-mediated immunosuppressive properties [23] . Plasmapheresis This is used for removing antibodies from the circulation. Reduction in antibodies triggers production of new antibodies as a result of a feedback mechanism [23] . mustard. These bind to DNA and inhibit its replication, which leads to cell death. It can be given orally as well as intravenously. One report described cyclophosphamide use in seven patients for treating PV in combination with corticosteroids and azathioprine [26] .
Nicotinamide and tetracycline These were used as steroid-sparing agent in combination with corticosteroids and azathioprine in one study of six patients with PV. Their mechanism of action is unclear [27] . Overall, the mortality and morbidity from PV and the medications used in its treatment are considerably lower in the more recent publications than in the early reports.
The reported treatment response in patients with PV has varied significantly. Prognostic factors that have been identified include initial severity and extent of disease, with higher severity being predictive of poorer prognosis. [29] . Perhaps related to this is the fact that early initiation of treatment before the disease becomes too severe or widespread has been associated with improved prognosis [30, 31] . Once treatment is initiated, good initial response to treatment has also been found to be indicative of a better prognosis [32] .
Most reports described medication courses of long duration before remission off therapy was achieved (between 5 and 10 years in the majority of patients with the range across all studies being 3 months to 27 years). However, Herbst and Bystryn described a group of 40 patients in whom 10 (25 %) patients achieved complete and long-lasting remission within 2 years of treatment; a subgroup of patients with PV, with a mild course of the disease requiring short courses of systemic medications or topical medication alone to induce remission [5, 32, 33] ; and at the other extreme a subgroup that is resistant to treatment and required high doses and prolonged therapy have also been described [29, 32, 35] .
The role of baseline laboratory tests, such as quantification of antibodies as predictors of disease course, has not been established. A recent study reported that a higher level of anti-Dsg1 autoantibodies (C100 U/mL) at diagnosis was associated with poorer prognosis
